Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Veracyte (VCYT – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Viridian Therapeutics (VRDN – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veracyte (VCYT)
In a report released today, Subbu Nambi from Guggenheim reiterated a Buy rating on Veracyte, with a price target of $50.00. The company’s shares closed last Tuesday at $37.74.
According to TipRanks.com, Nambi is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veracyte with a $46.33 average price target, a 20.8% upside from current levels. In a report issued on January 22, TipRanks – OpenAI also upgraded the stock to Buy with a $47.00 price target.
See today’s best-performing stocks on TipRanks >>
Sarepta Therapeutics (SRPT)
In a report released today, Biren Amin from Piper Sandler maintained a Hold rating on Sarepta Therapeutics, with a price target of $16.00. The company’s shares closed last Tuesday at $20.28.
According to TipRanks.com, Amin is a 4-star analyst with an average return of
Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $22.47, representing an 8.2% upside. In a report issued on January 20, Evercore ISI also maintained a Hold rating on the stock with a $17.00 price target.
Viridian Therapeutics (VRDN)
In a report released today, Serge Belanger from Needham assigned a Buy rating to Viridian Therapeutics, with a price target of $42.00. The company’s shares closed last Tuesday at $31.90.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
Viridian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $41.40, which is a 25.2% upside from current levels. In a report issued on January 20, Evercore ISI also maintained a Buy rating on the stock with a $44.00 price target.
